UK Veterinary Sector Faces Price Caps and IPO Ambitions

15/09/2025

The UK veterinary sector is at a crossroads. The Competition and Markets Authority (CMA) is weighing reforms that could fundamentally reshape how veterinary care is priced and delivered. Among the measures under discussion: capping medicine mark-ups, abolishing prescription fees, and banning incentive payments tied to certain treatments.

The move comes amid mounting consumer frustration — average veterinary bills have risen by more than 60% in the past eight years (The Guardian).

Independent practices argue that compliance with new regulations would impose disproportionate costs, especially on smaller clinics with already thin margins. The fear is that rural and lower-income regions could face veterinary “deserts” if smaller businesses close. Larger corporate groups may absorb compliance costs more easily, but they too face pressure: investors expect profitability to remain high even under tighter controls.

Consolidation adds another layer. IVC Evidensia, one of Europe’s largest veterinary chains, is reported to be preparing for a London IPO backed by EQT, Silver Lake, and Nestlé. Such a move would not only raise fresh capital but also anchor corporate veterinary groups more firmly in public markets, with all the transparency and scrutiny that implies.

The economic consequences cut both ways. For consumers, reforms may lead to lower costs and greater transparency in the short run. For the industry, they could accelerate the shift from independent practice toward consolidated corporate ownership, changing the very fabric of veterinary healthcare delivery.